A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)

Trial Profile

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs SEphB4-HSA (Primary)
  • Indications Cholangiocarcinoma; Liver cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results (n=29) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 23 May 2018 Planned End Date changed from 6 Sep 2019 to 6 Sep 2020.
    • 23 May 2018 Planned primary completion date changed from 6 Sep 2018 to 6 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top